AV-101

Summary

Av-101 (CHEMBL3545351) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including pulmonary arterial hypertension and major depressive disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 7
• Chemistry: 242.66 Da · C10H11ClN2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3545351
Name	AV-101
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	173480
Molecular formula	C10H11ClN2O3
Molecular weight	242.66
InChIKey	HQLHZNDJQSRKDT-UHFFFAOYSA-N

SMILES: C1=CC(=C(C=C1Cl)N)C(=O)CC(C(=O)O)N

IUPAC name: 2-amino-4-(2-amino-4-chlorophenyl)-4-oxobutanoic acid

Also known as: Av-101, J578.071C, AV-101

Patent coverage: 96 distinct patent families (215 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 209 (97%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
pulmonary arterial hypertension	3	MONDO:0015924	EFO:0001361
major depressive disorder	2	MONDO:0002009	MONDO:0002009
depressive disorder	2	MONDO:0002050	MONDO:0002050
neuralgia	1	MONDO:0021667	EFO:0005762

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE2	2
PHASE1	2
PHASE2/PHASE3	1
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05036135	PHASE2/PHASE3	TERMINATED	A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
NCT05557942	PHASE3	TERMINATED	Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)
NCT03078322	PHASE2	COMPLETED	AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression
NCT03583554	PHASE1/PHASE2	COMPLETED	Electrophysiological Biomarkers of AV-101
NCT04147949	PHASE2	UNKNOWN	AV-101 (L-4-chlorokynurenine) in Parkinson’s Disease Subjects With Levodopa-Induced Dyskinesia
NCT01483846	PHASE1	COMPLETED	Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers
NCT05280054	PHASE1	UNKNOWN	AV-101 Alone and in Combination With Probenecid in Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).